For additional information and poli- cies regarding guideline development, we encourage readers to consult the ACC/AHA guideline methodol- and other methodology articles.P-5 P-8 Selection of Writing Committee Members The Task Force strives to avoid bias by selecting experts from a broad array of backgrounds. Writing commit- tee members represent different geographic regions, sexes, ethnicities, races, intellectual perspectives/biases, and scopes of clinical practice. The Task Force may also invite organizations and professional societies with re- lated interests and expertise to participate as partners, collaborators, or endorsers. Relationships With Industry and Other Entities The ACC and AHA have rigorous policies and methods to ensure that guidelines are developed without bias or improper influence. The complete relationships with industry and other entities (RWI) policy can be found CLINICAL STATEMENTS AND GUIDELINES online. Appendix 1 of the current document lists writing committee members relevant RWI. For the purposes of full transparency, writing committee members compre- hensive disclosure information is available online, as is the comprehensive disclosure information for the Task Force. Evidence Review and Evidence Review Committees When developing recommendations, the writing com- mittee uses evidence-based methodologies that are based on all available data.P-4 P-7 Literature searches focus on randomized controlled trials (RCTs) but also include registries, nonrandomized comparative and descriptive studies, case series, cohort studies, systematic reviews, and expert opinion. Only key references are cited. An independent evidence review committee (ERC) is commissioned when there are 1 questions deemed of utmost clinical importance that merit formal systematic review. This systematic review will strive to determine which patients are most likely to benefit from a test, med- ication, device, or treatment strategy and to what degree. 